Ginkgo, Tangible and Inductive Bio aim to move ADME decisions from lead optimization to hit ID

Ginkgo, Tangible, and Inductive Bio launch ADME-One, combining AI and automation to deliver human PK and ADME projections earlier in drug discovery. For years, many small-molecule teams have treated comprehensive Absorption, Distribution, Metabolism and Excretion (ADME) profiling as a lead-optimization step. That is, it serves as a place to spend heavily once a lead series has already emerged. Now, Ginkgo Datapoints, Tangible Scientific and Inductive Bio are betting that AI, automation and tighter compound logistics can move that decision point much earlier. The new ADME-One platform packages Ginkgo’s automated Tier 1 assays, Tangible’s compound-management workflow and Inductive Bio’s human pharmacokinetic…

Source: Drug Discovery & Development